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ABSTRACT
While nicotine replacement therapy (NRT) is presumed to be a safer alternative to smoking
in pregnancy, the long-term consequences in offspring are still largely unknown. Animal
studies now suggest that maternal nicotine exposure during pregnancy and lactation (MNEPL) leads to a wide variety of adverse outcomes for the offspring, including increased
adiposity. The focus of this study was to investigate how MNE-PL in rats may lead to liver
dysfunction long-term in offspring through alterations in gene expression and epigenetic
modifications. Postnatal day 180 (PND180) offspring exposed to nicotine during pregnancy
and lactation (1mg/kg/day) exhibited increased circulating and hepatic triglycerides
concomitant with increased expression of fatty acid synthase (FAS), an enzyme involved in
hepatic de novo fatty acid synthesis. Furthermore, we demonstrate that MNE-PL offspring
displayed increased protein expression of the Liver X Receptor α (LXRα), a key regulator of
FAS. Chromatin immunoprecipitation revealed enriched binding of LXRα to the putative
LXRE element on the FAS promoter in PND180 male offspring. This was associated with
enhanced acetylation of histone H3 [K9,14] surrounding the FAS promoter, a hallmark of
chromatin activation. Collectively, these findings suggest that nicotine exposure during
pregnancy and lactation leads to increased circulating and hepatic triglyceride levels longterm via changes in transcriptional and epigenetic regulation of the hepatic lipogenic
pathway.

Keywords: Nicotine Replacement Therapy (NRT), Triglycerides, Fatty Acid Synthase
(FAS), Liver, Liver X Receptor (LXR), Obesity, Fetal Programming
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CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW

1.1 Nicotine
1.1.1

Maternal smoking and obesity
Despite the well-established links between smoking during pregnancy and

increased risk of placental complications (1), impaired fetal growth (2, 3) and perinatal
mortality (2, 3), approximately 10-20% of Canadian mothers continue to smoke during
pregnancy (4, 5). This translates to approximately ~75,000 babies born each year in
Canada alone who were exposed to first hand smoke in utero (2, 5). Unfortunately, the
global prevalence of tobacco smoking in young mothers continues to rise in low- and
middle-income countries (6). In addition, over half of the women who are able to quit
smoking during pregnancy will relapse within four months of delivery (7). If women
cannot abstain from smoking during pregnancy, a recent meta-analysis of thirty
prospective studies now suggests that their children have a 47% increase in the odds of
becoming overweight (8). Since smoking during pregnancy is a highly modifiable risk
factor, women are willingly predisposing their children to obesity at birth (9). It is
noteworthy to mention that some studies have identified a higher risk of children being
overweight if their mother was overweight prepregnancy (10). However, the association
between smoking and childhood obesity was found to be unaffected by maternal diet,
parental body size or gestational weight gain(11, 12). Therefore pathways independent of
a mother’s lifestyle may be playing a role in the long-term health and disease risk in
children. Numerous clinical studies have now found that adults exposed to smoking in
utero have increased plasma triglycerides, a characteristic often associated with obesity
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and the metabolic syndrome (13-16). This is of great concern considering that elevated
plasma triglycerides levels are an independent risk factor that is significantly associated
with cardiovascular (CV) disease (17, 18). Given that nearly one-third of Canadian
children and youth (5- to 17- years old) are either overweight or obese (19), and the risk
that elevated triglycerides pose (17, 18), it is clear that these situations warrant strategies
for the prevention or reduction of hypertriglyceridemia.
1.1.2

Nicotine replacement therapy (NRT)
Although cigarette smoking is one of the most important and modifiable risk

factors leading to adverse obstetrical outcomes (2, 9), nicotine dependence still remains
the driving force behind continued smoking behaviour (20-22). Consequently, nicotine
replacement therapy (NRT) has been widely developed as an effective therapy for
smoking cessation (20, 22). NRT provides a substitute source of nicotine that
significantly reduces the symptoms of cigarette withdrawal including irritability, hunger
and sleepiness (23, 24). NRT exists in various forms including gums, transdermal
patches, nasal sprays, inhalers and lozenges that differ in route of administration and dose
of nicotine (25). All NRT formulations are considered more effective as either the main
or supportive therapy used, compared to placebo or no treatment in smoking cessation
(26). The efficacy of NRT is largely based on the individual and will differ between
people based on factors such as the setting in which NRT is administered, source of
motivation for quitting and a smoker’s level of dependency on nicotine (27). A
systematic review of studies evaluating the commercially available forms of NRT found
that NRT alone increases the odds of smoking cessation 1.5 to 2-fold independent of
additional support and setting (28, 29).
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It is important to give special consideration to pregnant women using NRT
because of the harm nicotine exposure may pose for the developing fetus. Although NRT
appears to be a safer alternative to smoking in pregnancy as the number of chemicals is
reduced from 4000 to 1, there is little evidence validating this claim (30, 31). To date,
there is insufficient data available on the effectiveness of NRT during pregnancy or on
the potential risks it may pose (32). Despite this oversight, obstetricians continue to
prescribe NRT in pregnancy, highlighting the urgent need to study both safety and
efficacy of NRT in this population (33, 34). Moreover, understanding the long-term
consequences of maternal nicotine exposure (MNE) in offspring can provide insight into
determining a safe dose and management of NRT use in pregnancy.
In addition to the numerous health benefits of abstaining from smoking in
pregnancy, prenatal smoking cessation therapies provide additional economic benefits.
For instance, approximately every dollar invested in smoking cessation therapies can
result in up to three dollars saved in costs from the prevention of neonatal complications
and neonatal intensive care unit expenses (35).
1.1.3

Pharmacology of nicotine
Nicotine (C10H14N2) is a weak base and a relatively lipophilic compound, which

facilitates its ability to cross cell membranes in its unionized form (36-38). Accordingly,
various forms of NRT are buffered in an alkaline pH for absorption by the body (36). In
contrast to nicotine absorption from cigarette smoke, NRT results in a gradual absorption
of nicotine and reduces the likelihood of abuse by users (36, 39). Nicotine is absorbed
with high affinity in the brain, muscle, liver, lung, spleen and kidney (40, 41). Due to the
biological nature of nicotine, it is able to cross the placenta and mammary glands leading
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to the accumulation of nicotine in fetal serum and breast milk, respectively (42-45).
Studies have demonstrated that human fetuses are exposed to higher levels of nicotine in
the placenta, amniotic fluid and serum compared to levels measured in the maternal
serum (46).
1.1.4

Pharmacokinetics of nicotine
Nicotine is primarily metabolized in the liver and to a small degree in the lung

and brain (36, 47-49). Phase I metabolism of nicotine is mainly via the C-oxidation
pathway, which converts nicotine to cotinine. The C-oxidation pathway accounts for
approximately 72% of total nicotine metabolism (50). C-oxidation begins with the
conversion of nicotine to a nicotine ∆1’(5') iminium ion catalyzed by the liver cytochrome
P450 2A6 (CYP 2A6) enzyme (51-53). Genetic variations of this gene are postulated to
be the cause of inter-individual variability in nicotine metabolism (54). The nicotine ∆1’
(5')

iminium ion is converted by an aldehyde oxidase, the main enzyme involved in the

final step of the metabolism to cotinine (52, 55-57). Cotinine may be further metabolized
into a variety of metabolites, including the largest single metabolite 3’-transhydroxycotinine via CYP 2A6 (53). Nicotine and its metabolites undergo phase II
metabolism through a variety of glucoronidation reactions that convert the parent
substrates into more water-soluble compounds for excretion (36, 58-60). Finally, nicotine
and its metabolites are eliminated predominantly through renal excretion and to a small
degree in sweat and breast milk (61-64).
It is important to consider the changes in nicotine and cotinine clearance rates that
occur during pregnancy. In pregnancy, nicotine metabolism increases by approximately
50%, while nicotine absorption does not differ between pregnancy and postpartum (41,
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65). Correspondingly, cotinine metabolism increases by 140% (65). The elevations to
nicotine and cotinine metabolism in pregnant women are postulated to be a result of
increased hepatic metabolism by CYP 2A6 concomitant with faster levels of
glucuronidation (65). Although an increase in blood flow to the liver could explain an
increase in nicotine metabolism, nearly no difference is found in blood flow to the liver
during pregnancy (65). Therefore, increased clearance rates are likely due to an induction
of drug metabolizing enzymes in the liver during pregnancy (65, 66). Further
investigation is warranted to determine if the effective dosage of NRT should be
increased in order to accommodate the physiological changes in pregnancy (65).
1.1.5

Action of nicotine
Nicotine is a tertiary amine that binds to nicotinic acetylcholine receptors

(nAChRs) found mainly in the brain, autonomic ganglia and at neuromuscular junctions
(67). Upon binding, nAChRs undergo allosteric changes that increase their permeability
to calcium ions and trigger the release of neurotransmitters such as acetylcholine,
norephinephrine, dopamine, and serotonin (68). Specifically, the binding of nicotine to
the α4β2 nAChR likely mediates nicotine dependency (69). The addictive nature of
nicotine has been linked to the subsequent release of dopamine that leads to pleasurable
experiences, mood modulation and stimulation (69). Nicotine addiction develops due to
its positive reinforcing effects while avoiding withdrawal symptoms such as anxiety and
stress (68).
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1.2 Lipogenesis
1.2.1

Overview of the development and functions of the liver
Liver development begins in endodermal cells in the ventral foregut that are

specified for a hepatic fate. Through the coordination of a network of transcription
factors, these cells express new genes such as albumin and α-fetoprotein that commit
cells to develop into hepatoblasts. Hepatoblasts in the liver will bud and eventually
differentiate into hepatocytes or bile duct cells. Hepatocytes, the primary cells of the
liver, undergo extensive morphology and maturational changes before and after birth in
both rodents and humans (70, 71).
The cells within the liver are highly organized in order to carry out a myriad of
functions. In brief, blood enters the liver through the hepatic artery and leaves through the
hepatic vein. Blood travels through the liver via sinusoids, which consist of small
capillaries, lined with highly fenestrated endothelial cells to allow for the exchange
between the bloodstream and hepatocytes. The structure of the liver allows for the
compartmentalization of function depending on the location of hepatocytes. As a result,
hepatocytes are able to carry out various metabolic pathways in distinct regions of the
liver (71).
The liver possesses several vital functions in the body including the production of
bile, detoxification of xenobiotic agents, breakdown of toxic endogenous compounds,
maintenance of cholesterol homeostasis, regulation of gluconeogenesis and the synthesis
and metabolism of lipids (71).
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1.2.2

The role of the liver and adipose tissue in lipogenesis
Lipogenesis is the synthesis of fatty acids and the subsequent formation of

triglycerides, which mainly occurs in the liver and adipose tissue (72). Fatty acids can
become oxidized or undergo esterification reactions to form triglycerides (73). The liver
maintains lipid homeostasis in part through a balance between lipid storage and lipid
metabolism. The liver obtains free fatty acids from either lipolysis of adipose tissue or
through de novo fatty acid synthesis (73). Interestingly, it has been shown that both de
novo lipogenesis and reesterification of peripheral fatty acids contribute to the elevated
levels of triglycerides observed in patients with abnormal lipid accumulation in the liver
(74).
In addition to the liver, adipose tissue also plays a fundamental role in
lipogenesis. Adipose tissue constitutes a large energy reservoir in the body that stores
energy in the form of triglycerides that are absorbed from the circulation (75, 76). Almost
90% of adipocyte cell volume is made up of lipid droplets consisting of fats,
triglycerides, fatty acids, phospholipids and cholesterol (75). In response to lipid
requirements by other tissues, triglycerides in adipose tissue are hydrolyzed and released
into the bloodstream as free fatty acids and glycerol molecules (77). Although adipose
tissue can undergo de novo lipogenesis, studies have shown that it does not greatly
contribute to the maintenance of excess fat in obese patients (78). In contrast, enhanced
hepatic lipogenesis has been found to contribute to increased triglyceride pools and
maintenance of excess fat in obese patients (78).
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1.2.3

Hepatic de novo lipogenesis
Lipid synthesis in the liver begins with the uptake of glucose through the glucose

transporter 2 (Glut2) (79). Once glycogen stores have been maximized, excess glucose is
converted into triglycerides (80). Glucose enters the glycolytic pathway to form pyruvate,
which then undergoes decarboxylation reactions by pyruvate dehydrogenase to form
acetyl-CoA(81-84). Acetyl-CoA carboxylase (ACCα), a cytoplasmic enzyme, converts
acetyl-CoA to malonyl-CoA, a committed step in fatty acid synthesis (85). Malonyl-CoA
is essential for the production of long chain fatty acids such as palmitate and is a substrate
for the fatty acid synthase (FAS) enzyme (85, 86). FAS catalyzes the conversion of
palmitate to its major product palmitic acid through successive additions of malonyl-CoA
to an acetyl-CoA molecule (87). Subsequently, stearoyl-CoA desaturase-1 (SCD-1)
located in the endoplasmic reticulum (ER) converts palmitoyl- and stearoyl-CoA into
monounsaturated fatty acids (MUFAs), palmitoleate and oleate, respectively (88).
MUFAs undergo further desaturation and elongation reactions before becoming
incorporated into various lipid products including triglycerides (Fig 1.2.3) (88).
Gene knockdown studies in mice have been used to elucidate the source of
MUFAs used in triglyceride incorporation. Mice lacking SCD-1 were found to have
approximately 60% lower liver and circulating triglyceride levels compared to
heterogeneous mice (89). Notably, an exogenous source of MUFAs was unable to rescue
the abnormal triglyceride profile in deficient mice, suggesting that endogenously
synthesized MUFAs are the main substrate for hepatic de novo triglyceride synthesis
(89). Given that endogenous MUFAs are formed in the ER, they are in close proximity to
the enzymes involved in triglyceride synthesis. Therefore, endogenous MUFAs are more
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readily available at the site of triglyceride synthesis compared to MUFAs derived from
dietary sources (89, 90).
Triglycerides consist of a glycerol moiety with fatty acids eesterified
sterified to all three
hydroxyls (91).. While studies have implicated enhanced hepatic lipogenesis in patients
with augmented plasma triglycerides, the role of the individual fatty acid biosynthetic
enzymes in nicotine-induced
induced hypertriglyceridemia is currently unknown (13, 14, 78)

Fig. 1.2.3 Overview of the hepatic de novo triglyceride synthesis pathway.
The synthesis of fatty acids requires key enzymes including acetyl Co-A
Co
carboxylase (ACCα)) and fatty acid synthase (FAS). Stearoyl
Stearoyl-CoA
CoA desaturase 1
(SCD-1)
1) is required for the desaturation of fatty acids, while elongase (Elovl)
enzymes,

glycerol--3-phosphate

acyltransferase

(GPAT)
GPAT)

acyltransferase (DGAT
DGAT) are required for triglyceride synthesis.

and

diglyceride
d

10

1.2.4

The regulation of lipogenic genes
Nutritional status and hormones are well known regulators of lipogenesis. Studies

examining the effect of nutrition supplementation in rats, have found that fasted animals
have significantly lower FAS enzymatic activity in the liver compared to fed animals (92,
93). Moreover, refeeding was shown to lead to an increase in absolute protein content of
hepatic FAS by 30- to 50-fold in rats (93). Two major mechanisms have been considered
linking nutritional status and the transcriptional regulation of lipogenesis. Firstly being
that glucose itself is a substrate for lipogenesis, and secondly that glucose stimulates the
release of insulin (72, 94).
Insulin has been identified as an important regulator of lipogenesis.
Streptozotocin (STZ)-induced diabetic mice show that treatment with insulin resulted in a
rapid restoration of FAS enzymatic activity and mRNA levels. Although the rates of FAS
activity decreased over time, the induction of steady-state mRNA was maintained three
days after insulin administration, demonstrating that insulin primarily stimulates the
transcription of the FAS gene (92). Insulin is able to exert its regulatory effect through
the action of the transcription factor, sterol regulatory element-binding protein -1c
(SREBP-1c). Studies in primary cultured rodent hepatocytes found that in the absence of
insulin, SREBP-1c was not expressed. However, the addition of insulin led to an
induction of SREBP-1c protein expression (95, 96). Furthermore, in vivo studies have
demonstrated that SREBP-1c deficient mice, exposed to either fasting-refeeding
treatments or a prolonged high carbohydrate diet, situations during which SREBP-1c
would be expected to be expressed, exhibited lower induction of lipogenic genes (97).
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Therefore, SREBP-1c is crucial for mediating the regulatory effects of insulin on hepatic
lipogenesis.
A multitude of regulatory mechanisms are necessary to maintain lipid
homeostasis. Nuclear receptors such as the liver X receptor (LXR) are unique ligand
activated transcription factors that are able to sense lipids and directly influence
transcriptional regulation. Interestingly, LXR has been demonstrated to regulate SREBP1c and thus likely contributes to the control of hepatic lipogenesis as well. LXR deficient
mice were found to have decreased hepatic SREBP-1c expression. When treated with the
LXRα agonist, T0901317, LXR deficient mice did not exhibit an induction in hepatic
lipogenic genes compared to control mice (98). LXR is considered an intermediary
component of the insulin-sensing pathway as insulin treatment resulted in the induction
of LXRα mRNA as observed in both in vitro and in vivo studies (99). LXR has a
comprehensive regulatory role over many components of the lipogenesis pathway and
will therefore be the primary focus of my thesis.
1.3 The liver X receptor
1.3.1

Overview of the liver X receptor
The liver X receptors (LXRα and LXRβ) are nuclear receptors that are involved

in the regulation of cholesterol, lipid and glucose homeostasis (100). LXR is located
within the nucleus and heterodimerizes with the retinoid X receptor (RXR) upon
activation (101). LXR is regarded as a permissive nuclear receptor as either LXR or RXR
ligands can activate the dimer (102-104). Although LXRα and LXRβ isoforms share
approximately 77% homology, they differ in their expression profiles (105). LXRα is
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predominantly expressed in the liver, intestines, kidney, spleen and testes (106), while
LXRβ is ubiquitously expressed in the body (101, 106, 107). LXR/RXR heterodimers
bind to specific LXR binding element motifs (LXRE) in the promoter of genes, which
consist of direct repeats (DR-4) of the AGGTCA sequence separated by 4 nucleotides
(101).
1.3.2

LXR and cholesterol synthesis
The discovery of the endogenous activators of LXRα helped to elucidate the

biological role of this nuclear receptor. Early studies demonstrated that oxysterols such as
24(S)-hydroxy-cholesterol and 22(R)-hydroxycholesterol lead to the activation of LXRα
(104, 108). Upon ligand binding, LXRα was observed to bind to the cholesterol 7αhydroxylase promoter (CYP7A), the rate-limiting enzyme in cholesterol catabolism.
These data provided early indication of the role of LXRα in cholesterol homeostasis,
specifically the conversion of cholesterol to bile acid (104, 108, 109). Gene knockdown
studies in mice have since demonstrated that when challenged with a cholesterol rich diet,
LXRα deficient mice are unable to catabolize excess cholesterol and experience less bile
acid synthesis compared to control mice. In addition, there was no compensatory effect
by LXRβ, further confirming differential gene expression regulation by the LXR
isoforms (110). Oxysterol binding to LXRα leads to the activation of other targets such
as ATP-binding cassette transporter 1 (ABC1) and inhibits low-density lipoprotein
receptor (LDLR) involved in cholesterol efflux and uptake, respectively (111-113).
Therefore, LXRα was originally characterized as a cholesterol sensor in the maintenance
of cholesterol homeostasis.
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Interestingly, LXRα deficient mice also exhibited changes related to other hepatic
pathways including fatty acid synthesis. Key enzymes and factors in the fatty acid
biosynthetic pathway such as SCD-1, FAS and SREBP-1c, were down regulated in the
liver of knockout mice. Furthermore, increased lipid deposits in the liver observed in the
liver of deficient mice implicate a broader role of LXRα (110).
1.3.3

LXR and fatty acid synthesis
In addition to SREBP-1c, LXRα has been implicated to play a direct role in

hepatic fatty acid synthesis (114, 115). LXR deficient mice exhibited decreased plasma
triglyceride levels and free fatty acids concomitant with depressed fatty acid synthesis
rates between 60-80% (100). Studies using potent nonsteroidal LXRα agonists such as
T09013177 and GW3965 have helped characterize the regulatory role of LXRα (115,
116). Notably, both synthetic agonists are highly selective for LXR α and β over several
other nuclear receptors including, RXR and constitutive androstane receptor (CAR) (115,
116). Small animal studies have demonstrated that treatment with T0901317 led to
significant increases in plasma triglyceride levels, which was associated with an
induction in the activity of FAS, ACCα, SCD-1 and SREBP-1c in mice and hamsters. To
further elucidate the role of LXRα in fatty acid synthesis, LXR deficient mice treated
with LXRα agonist found that animals exhibited blunted expression of fatty acid
biosynthetic genes compared to wild type mice (115). Thus, another layer of fatty acid
regulation by LXR was uncovered.
However, it remained unknown whether LXRα had a direct and separate
regulatory role from SREBP-1c. An in vitro model demonstrated that the treatment of
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TPH-1 macrophages with LXR agonists T0901317 or GW3965 led to the activation of
LXR and increased FAS mRNA expression despite the active suppression of SREBP-1c
expression (117). Moreover, a temporal relationship was observed in LXRα agonist
treated mice as triglyceride levels increased with rising FAS gene expression. Therefore,
it was determined that LXRα was able to directly activate FAS and contribute to
increased triglyceride production in a SREPB-1c independent manner (117). From these
experiments, an LXRE was identified between -669 and -655 base pairs (bp) in the rat
FAS promoter, which is also highly conserved in humans (118). Similarly, SREBP-1c has
also been shown to bind directly to highly conserved tandem sites between -71 and -54
bp in the rat FAS promoter (119). With the existence of both binding sites, luciferase
activity assays have demonstrated that the activation of both LXRα/RXR and SREBP-1c
leads to the additive activation of FAS (117). LXRα has been established to directly and
indirectly control hepatic fatty acid synthesis.
Likewise, LXR is able to directly target additional enzymes along the fatty acid
synthesis pathway. Studies eliminating SREBP-1c expression, found that treatment with
an LXR agonist in mice results in an increase in MUFAs and triglycerides via the
activation of SCD-1 expression. Furthermore, researchers have identified an LXR
binding site in the mouse promoter of SCD-1 between positions -1263 and -1248 bp
(120). LXR can also directly interact with the promoter of ACCα between -101 and -71
bp. Similarly, LXR agonist treatment led to an increase in ACCα mRNA expression
independent of SREBP-1c binding in chick embryos (121). This is of importance as
changes in ACCα expression are vital in overall triglyceride levels (121). In summary,
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LXR-mediated changes in fatty acid synthesis can lead to significant downstream
alterations in triglyceride levels.
1.3.4

LXR and glucose regulation
In contrast to the activating role of LXR in cholesterol and fatty acid homeostasis,

LXR plays a suppressive role in the regulation of hepatic glucose metabolism (122).
Studies have demonstrated in mice treated with LXR agonist GW3965, resulted in the
upregulation of hepatic lipogenic targets while repressing peroxisome-proliferator
activate-receptor coactivator-1 (PGC-1), a transcriptional coactivator necessary for the
activation of a plethora of hepatic gluconeogenic genes (123, 124). While my thesis
focuses mainly on fatty acid synthesis, LXR activation can lead to coordinated glucose
regulation in adipose tissue and skeletal muscle (122, 125). Studies demonstrate that
GW3965 treated mice exhibit increased Glut4 mRNA levels in adipose tissue, while
T0901317 treatment in human myotubes leads to increased glucose uptake (122, 125).
Together, these studies suggest that LXR activation helps to maintain glucose levels by
promoting peripheral glucose uptake while suppressing gluconeogenesis in the liver.
LXR may be the key link in the control of lipid and glucose metabolism whereby LXR
limits the production of glucose in the liver while promoting glucose uptake and
stimulating de novo lipogenesis for storage of excess energy as triglycerides in adipose
tissue (122). Furthermore, treatment with an LXR agonist has been shown to improve
glucose tolerance in mouse models of obesity and insulin resistance (122). Although
modulation of LXR activity would appear to be a promising therapy for the treatment of
diabetes and hyperglycemia, it is important to resolve and balance the impact of LXR
regulation on fatty acid and cholesterol homeostasis as well.
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1.4 Epigenetics
1.4.1

Overview of epigenetics
In recent years epigenetics has emerged as a dynamic form of regulation that

relies on the information that is held in how the genome is packaged. Although various
definitions of epigenetics have been put forth, it is broadly defined as the structural
adaptations of chromosomal regions that can signal altered states of activity (126).
Therefore, transcription can be turned “on” or “off”, depending on the packaging of
genes (127).
DNA is wrapped around an octamer of histones, consisting of two copies of
histones H2A, H2B, H3 and H4 to form a nucleosome, the main packing element of
genomic DNA (128, 129). DNA binding to histones is facilitated through an electrostatic
interaction between the positively charged peptides and negatively charged DNA
backbone (130). Nucleosomes are linked together by 10 to 60 bp of DNA that are
associated with histone H1 to form higher order chromatin structures (131). Histones
possess N- (NH2-) and C-terminus (COOH-) tails that emanate out of the nucleosome
and are susceptible to covalent modifications such as methylation, acetylation,
phoshorylation, ubiquinitination and ADP-ribosylation (127, 131, 132). Alterations to
histones can lead to large functional modifications in transcription, revealing a “histone
code” that confers states of transcriptionally silent heterochromatin and active
euchromatin (127, 133, 134).
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Fig. 1.4.1 Overview of the role of posttranslational histone modifications (acetylation
and methylation) in transcriptional regulation

1.4.2

Histone acetylation
One of the first pieces of evidence of the histone code was demonstrating that

histone acetylation
ylation results in an increase in RNA synthesis (133).. Early studies observed
that an increase in histone acetylation preceded an increase in RNA and protein synthesis
in human lymphocytes (135)
(135).. Histone acetylation has since been found to dictate the
transition to transcriptionally active chromatin by increasing the accessibility of gene
templates to transcription factors, which are inhibited by the structure of the nucleosome
in the absence of acetylation (136). Histone acetylation
cetylation increases accessibility by
reducing the number of positive charges and disrupting the uniform charge distribution of
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positively charged lysine and arginine residues of histone amino tails (130). For that
reason, the stability of DNA wrapped around peptides has been found to be five times
less stable and possess a greater number of uncoiled base pairs compared to nonacetylated peptides (130, 137). Histone acetylation commonly occurs on the N-terminal
of histones H3 and H4, as studies have demonstrated that replacement of N-terminal
residues silences the effects of histone deacetylases (HDAC) (138-140). Histone
deactylases such as the family of sirtuin enzymes facilitate the removal of acetyl groups
and contribute to the formation of heterochromatin (141).
Among the known posttranslational modifications, acetylation and deacetylation
have garnered the most attention (142). Enzymes, namely histone acetyltransferases
(HAT), are responsible for the acetylation of histone tails. HATs were found to possess
domains

that

were

homologous

for

yeast

adaptor

proteins

indicating

that

acetyltransferases are also recruited in a gene specific manner (143, 144). HATs are
classified based on their function: A-type are involved in transcription whereas B-type
are involved in nucleosomal assembly. For example, p300/CBP are A-type HATs that
have been found to interact with many DNA-binding transcriptional factors (145).
1.4.3

Histone methylation
Histone methylation is a common posttranslational modification that is commonly

associated with the inhibition of gene expression (146). Histone methylation mediates
transcriptional silencing by acting as a signal for the recruitment of repressive complexes
that leads to deacetylation (147, 148). Methylation commonly occurs at lysine or arginine
residues on histones H3 or H4 in a mono-, di- or tri-methylated manner (149). Since the
discovery

of

histone

methylation

as

a

regulatory

signal,

several

histone
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methyltransferases (HMT) have been characterized. For example, the human SUV39H1
possesses catalytic activity and demonstrates site preference for methylation at the Nterminal of histone H3 (150).
1.4.4

Epigenetics and fetal programming
To date, there is very little data on the epigenetic regulation of LXR target genes.

However, studies have begun to reveal evidence of altered gene activation due to
posttranslational histone modifications. Treatment of chick embryos with LXR agonist
T0901317 led to a direct increase in ACCα mRNA expression increased LXR binding to
the LXRE within the 5’ upstream region of ACCα and enhanced acetylation of histone
H3 (151). In a similar fashion, treatment with T0901317 in human hepatocellular
carcinoma cell line (HepG2) led to an enrichment of histones H3 and H4 acetylation at
the LXRE of the FAS promoter. Further experiments showed that histone acetylation was
diminished in LXRα deficient cells, suggesting that LXRα expression was required for
these histone modifications (152). Although lipogenic genes can be subjected to
posttranslational histone modifications, it has yet to be concluded if chromatin
remodeling is associated in models of fetal programming. Our laboratory has begun to
shed light on permanent epigenetic changes due to insults during perinatal life. We have
previously shown that maternal protein restriction (MPR) through pregnancy and
weaning leads to long-term hypercholesterolemia in rat offspring as a result of impaired
Cyp7a1 expression, an LXR target gene (153). This decreased Cyp7a1 expression was
influenced by diminished acetylation and increased methylation at the LXRE of the
Cyp7a1 gene, promoting a repressive chromatin environment that persisted into
adulthood (153). Recently, we have also shown that MPR during pregnancy alone leads
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to the suppression of LXRα expression long-term due to decreases in the acetylation of
histone H3 [K9,14] and RNA polymerase II recruitment surrounding the proximal
promoter (-144 to +134 bp) of the LXR gene (154). Additionally, our laboratory has
explored the posttranslational modifications that occur in response to maternal hypoxia
during gestation in rat offspring. We demonstrated that maternal hypoxia led to decreased
glucose-6-phosphatase (G6Pase) mRNA and protein expression, concomitant with
increased methylation of histone H3 [K9] at the LXRE of the G6Pase promoter in 12
month old rat offspring (155). Our work supports that multiple models of fetal
programming are associated with posttranslational histone modifications of hepatic LXR
target genes and will continue to be explored in our model of MNE.
1.5 Developmental origins of health and disease (DOHaD)
1.5.1

History of DOHaD
Epidemiological data has demonstrated that poor fetal growth is strongly

correlated with various long-term developmental alterations in offspring including
increased risk for cardiovascular disease (156), high blood pressure (157), type two
diabetes (158, 159), and raised fasting serum triglyceride levels (160). It is important to
note that these relationships were found independent of confounding factors such as
alcohol consumption and social class of mothers, strengthening the studies supporting
DOHaD.
Early evidence of DOHaD in humans was observed during the Dutch famine, an
acute period of exposure to suboptimal nutrition. Studies examining this period of history
discovered that children exposed to poor nutrition in utero experienced decreased glucose
tolerance in later life (161). Similar studies in England found that low birth weight was
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associated with an increase in mortality from CV disease in adulthood (156, 162).
Growing evidence has supported the idea that developmental adaptations made in utero,
may lead to permanent changes or “programming” of the body (163). To help
characterize this phenomenon, Hales and Barker put forth “The Thrifty phenotype
hypothesis”. They proposed that the in utero environment provides cues of the postnatal
environment for the fetus, which causes the fetus to make thrifty adaptations for survival.
However, these once advantageous changes become detrimental if the postnatal
environment differs from the cues established in utero (158).
Since the conception of DOHaD, a wide range of adverse intrauterine
environments including alterations in oxygenation and hormone levels have been linked
to increased incidence of CV and metabolic disease in adult life (164).
1.5.2

Models of fetal programming
Animal models have helped to elucidate the mechanisms underlying DOHaD, and

shed light on the nature of the insult, timing and duration that lead to specific
physiological outcomes (164). Rodent models have demonstrated that even minor
changes in protein intake throughout pregnancy and lactation can lead to long-term
hypercholesterolemia in rat offspring (153). Furthermore, our laboratory has
demonstrated that MPR during gestation alone results in glucose intolerance in later life
(165). These studies revealed that the manifestation of features of the metabolic
syndrome in offspring does not solely rest on the type of insult, but the duration of the
insult in perinatal life. Other nutritional insults explored in animal models of fetal
programming include iron deficiency, high fat diet and micronutrient deficiencies (166168).
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Stress-related increases in glucocorticoids during pregnancy have been linked to
low birth weight and higher fasting plasma glucose levels in adult rat offspring (169,
170). Long-term programming, studies have demonstrated that 20 year old individuals,
who were all low birth weight, had higher cortisol levels compared to individuals who
were deemed appropriate weight for gestational age (171). This suggests that the
hypothalamaus-pituatary–adrenal axis could be susceptible to programming changes in
utero (171).
Hypoxia is a common consequence of placental insufficiency and has also been
implicated in the fetal programming of adult disease (172). Chronic maternal hypoxia
exposure in a rodent model has been shown to lead to decreased relaxation of mesenteric
arteries and increased risk for ischemic injury in adult life (173, 174). In concordance
with hypoxia-induced CV dysfunction, maternal hypoxia can also lead to permanent
impairments in glucose homeostasis. Livers of adult male rat offspring exposed to
hypoxia during gestation alone exhibited decreased G6Pase expression, an enzyme
necessary for the progression of the glycolytic pathway (155, 175). Consequently,
exposure to chronic maternal hypoxia can predispose offspring to a variety of disorders in
adulthood.
Although catch-up growth may not be a tangible in utero insult, it is nonetheless a
contributor to the fetal programming phenomenon. Catch-up growth is defined as a
child’s return to their genetic growth trajectory after experiencing a period of slowed
growth (176). For example, following MPR in rats, offspring that are fed a high caloric
diet in postnatal life have a propensity to catch up in weight and then continue to become
overweight compared to control rats (177). Similarly, children who experienced catch up
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growth between the ages of 0 and 2 years old, were more likely to have increased body
mass index (BMI) and fat mass at 5 years of age compared to other children their age
(176). Although it is generally accepted that regardless of age, an association exists
between rapid growth and being overweight as an adult (178), the underlying molecular
mechanisms are not well characterized.
In summary, human and animal studies have clearly established that physiological
changes that occur in response to the maternal environment in fetal and neonatal life can
impact an individual’s health long-term. Further understanding of the critical windows of
DOHaD could lead to novel therapies for the prevention of a variety of adult onset
diseases.
1.5.3

Fetal programming models of MNE
Animal models of MNE have been critical in understanding the effect of nicotine

exposure alone. Numerous studies on both smoking and nicotine have explored
alterations in brain, lung and reproductive outcomes in offspring (179-184). More
recently, MNE studies indicate that nicotine alone could be linked to the development of
features of the metabolic syndrome such as obesity (185).
Given the neurological risks observed in children of smoking mothers, animal
models have been imperative in investigating this underlying association. Rats exposed to
the equivalent amount of nicotine as smoking 3 packs per day via an osmotic pump,
exhibited a decrease in the number of rat fetal brain cells. Furthermore, it was found that
exposure to nicotine resulted in a delay in cerebellum maturation in rat offspring (186).
Using a similar method of nicotine delivery during pregnancy, one study observed an
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increase in the stimulation of cholinergic activity in the cerebral cortex of rat offspring
(187). This increased activity may lead to premature stimulation and disruptions to the
normal timing of postnatal brain development (187). In conjunction with developmental
impairments, prenatal nicotine exposure has been shown to influence behavioural
outcomes in offspring as well. Rat offspring exposed to nicotine in utero, were observed
to be more anxious and poorer adaptors compared to control offspring at PND45 (188).
These studies link nicotine as a critical component of cigarette smoke to the development
of neurological impairments in children exposed to smoke during pregnancy.
Children of smoking mothers also share strikingly similar compromises in lung
development and function observed in animal models of MNE (189). In rhesus monkey
and rodent studies of MNE during pregnancy, offspring were observed to have increased
collagen deposition around large airways, a potential precursor to lung fibrosis, in
newborn and 3 month old offspring, respectively (189, 190). Newborn monkeys exposed
to nicotine in utero also suffered significant impairment to lung development, decreased
function capacity and increased pulmonary resistance.
Interestingly, epidemiological evidence has now linked in utero exposure to
tobacco and the development of obesity in children (191). A variety of windows of
nicotine exposure have resulted in a spectrum of obese-related outcomes in offspring.
Nicotine exposure during pregnancy via the implantation of nicotine osmotic minipumps
in rats led to both early- and long-term alterations in rat offspring. During early neonatal
life, MNE rat offspring exhibited increased white adipose tissue and adipocyte
hypertrophy. Subsequently, these offspring continued to develop insulin resistance in
adulthood (185).

25

Notably, our rat model of maternal nicotine exposure during pregnancy and
lactation (MNE-PL) has already been found to lead to increased bodyweight, adiposity,
blood pressure, β-cell loss, impaired fecundity and glucose homeostasis long-term in
offspring (192-196). Importantly, this animal model is highly relevant to the human
population as the amount of nicotine used is equivalent to the amount of nicotine children
of average smokers are exposed to (192). In our rat model of MNE-PL, the dose of
nicotine results in maternal cotinine concentrations comparable to moderate smokers (80163ng/ml) and concentrations of cotinine measured in offspring that are within the range
(5-30ng/ml) observed in infants nursed by smoking mothers (192, 197, 198).
Furthermore, previous studies of this model of MNE-PL found there was no effect on
maternal food intake, eliminating maternal obesity as a confounding variable in the longterm programming of metabolic dysfunction in rat offspring (10, 192).
Surprisingly,

some

nicotine-induced

developmental

changes

have

been

transgenerational. Second-generation offspring of dams exposed to nicotine during
pregnancy and lactation, developed perturbations in blood pressure and insulin levels
despite the fact that these offspring were not directly exposed to nicotine themselves
(194, 199). In humans, limited data exists on the impact of a mother’s exposure to
smoking in utero on her children. One study has demonstrated that a smoking mother
exposed to smoke in utero, is more likely to have a lighter child compared to a smoking
mother who had not been exposed to smoke in utero (200).
1.6 Thesis hypothesis and objectives
Smoking during pregnancy is associated with numerous fetal and neonatal
complications short-term, along with increased risk of adult-onset diseases. While
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nicotine replacement therapy is widely prescribed in pregnancy as a pharmacotherapy for
smoking cessation, there is little information to date on the effects of maternal nicotine
exposure on long-term diseases processes. Animal studies suggest that nicotine exposure
alone during fetal and neonatal life may increase the risk of dyslipidemia and obesity in
postnatal life. This study aimed to investigate the permanent changes in liver function,
which may mediate in part the etiology of metabolic dysfunction rat offspring exposed to
nicotine during pregnancy and lactation.
Hypothesis:
We hypothesize that maternal nicotine exposure during pregnancy and lactation
will lead to long-term liver dysfunction in the offspring.
Objectives:
1) To determine whether maternal nicotine exposure during pregnancy and lactation leads
to changes in expression of hepatic fatty acid biosynthetic enzymes in rat offspring.
2) To examine the underlying transcriptional mechanisms and posttranslational histone
modifications that may be involved.
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CHAPTER 2 : MATERIALS AND METHODS

2.1 Maternal nicotine exposure during pregnancy and lactation (MNE-PL) animal
model
2.1.1

Animal care and drug administration
All animal experiments were performed at McMaster University and were

approved by the Animal Research Ethics Board at McMaster University, in accordance
with the guidelines of the Canadian Council for Animal Care. Nulliparous female Wistar
rats (200-250g, Harlan, Indianapolis, IN, USA) were randomly assigned to receive daily
subcutaneous injections of saline (vehicle) or nicotine bitartrate (1mg/kg/day, SigmaAldrich, St. Louis, MO, USA) for 2 weeks prior to mating, during pregnancy until
weaning (PND21) as previously described (195, 201). This dose of nicotine has been
previously shown to lead to cotinine concentrations in maternal serum (135.9±7.86
ng/ml) that fall within the range reported of “moderate” female smokers (80-163ng/ml)
and in serum cotinine concentrations (26.2±1.78 ng/ml) in offspring, that are comparable
to the range (5-30 ng/ml) found in infants nursed by smoking mothers (45, 192, 195,
198). Dams were allowed to deliver normally and at PND1 all litters were culled to eight.
At PND1 and PND21, subsets of male offspring were sacrificed by CO2 inhalation for
body weight measurements and liver tissue collection. All animals were weighed at
necropsy. Livers were snapped frozen in liquid nitrogen and stored at -80°C until
molecular analysis.
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A third subset of offspring were caged as sibling pairs and at PND180, male and female
rats were fasted overnight
night and sacrificed by CO2 inhalation
on for body weight
measurements. Livers were snapped frozen in liquid nitrogen and stored at -80°C until
molecular analysis. Blood was collected, allowed to clot, spun and serum was stored at 80°C until analysis (Fig. 2.1.1)
2.1.1).

Fig. 2.1.1 Overview of animal model of maternal nicotine exposure during
pregnancy and lactation. Pregnant rats were administered nicotine bitartrate or
saline (vehicle) for two weeks prior to mating until weaning. Offspring were
sacrificed at PND1,
1, 21 and 180 for analysis.
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2.1.2

Plasma and hepatic lipid measurements
Total cholesterol, triglyceride and glucose levels were measured from blood and

hepatic tissue samples using Cobas® analyzer at the Metabolic Phenotype Laboratory at
Robarts Research Institute (London, Ontario, Canada). Briefly, triglycerides are
hydrolyzed by lipoprotein lipase to glycerol and fatty acids. Glycerol is then
phosphorylated to glycerol-3-phosphate by ATP in a reaction catalyzed by glycerol
kinase (GK). The oxidation of glycerol-3-phosphate is catalyzed by glycerol phosphate
oxidase (GPO) to form dihydroxyacetone phosphate and hydrogen peroxide (H2O2). In
the presence of peroxidase, H2O2 alters the oxidative coupling of 4-chlorophenol and 4aminsophenazone to form a red-colored quinoneiminse dye, which is measured at 512
nm. The increase in absorbance is directly proportional to the concentration of
triglycerides in the sample.
2.2 Molecular analysis
2.2.1

Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA from male and female liver tissue was extracted at PND1, PND21 and

PND180 by the one-step method described by Chomczynski and Sacchi (202). RNA was
treated with deoxyribonuclease to remove any contaminating DNA. 4µg of the total RNA
was reverse transcribed to cDNA using random primers and Superscript II RNase Hreverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer sets directed for the genes
of

interest

(FAS,

ACCα,

SCD-1,

SIRT-1,

p300)

were

generated

using

OligoPerfect™Designer (Invitrogen, Carlsbad, CA, USA) (Table 2.2.1). The Bio-Rad
CFX384 Real Time System was employed to determine quantitative mRNA expression
using the DNA binding dye SsoFast™ EvaGreen® Supermix (Bio-Rad, Mississauga,
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Ontario, Canada). The cycling conditions were as follows: 50°C for 2 mins, 95°C for 10
mins, followed by 45 cycles of 95°C for 15 sec, and 60°C for 1 mins. The cycle threshold
was set at a level where the exponential increase in PCR amplification was roughly
corresponding between all samples. The relative fold changes were calculated using the
comparative cycle times (Ct) method with β-actin as the reference gene. All primer sets
were demonstrated to have good linear correlation (slope≈-3.4) strongly suggesting equal
priming efficiency (data not shown). ∆Ct values for each primer set were calibrated to the
experimental samples with the lowest transcript abundance (highest Ct value). The
relative abundance of each primer set compared with calibrator was determined by the
formula, 2∆∆Ct, in which ∆∆Ct is the calibrated Ct value.
Table 2.2.1 Primer sequences for quantitative real-time PCR analysis

Gene
FAS

Primer (5’-3’)
FWD GGA CAT GGT CAC AGA CGA TGA C

Reference No.
X62889.1

REV CGT CGA ACT TGG ACA GAT CCT T
ACCα

FWD TCC GTA TGT GAC CAA AGA CC

NM_022193.1

REV TAC GTT GTT CCC AAG GAC TG
SCD-1

FWD GCT TGT GGA GCC ACA GGA CTT AC

NM_031841.1

REV ATC CCG GGC CCA TTC ATA TAC
p300

FWD AGC GAG CTT ATG CTG CTC TC
REV GGC ACT CAT GTT GTT CAT GG

NW_001084859.1
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Sirt1

FWD AGC TGG GGT TTC TGT TTC CT

NC_005119.3

REV CTG GTT ATG CTC TTG GTG TCT TTC
β-actin

FWD CAG CCT TCC TTC CTG GGT AT

NM_031144.3

REV AGG AGC CAG GGC AGT AAT TCT

2.2.2

Protein extraction and western immunoblotting analysis
Tissue protein was extracted from snap frozen liver samples using RIPA lysis

buffer solution (50 mM Tris-HCl, pH 7.4, NP-40 1%, Na-deoxycholate 0.25%, 150 mM
NaCl, 1mM EDTA, 50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate) and a
protease inhibitor (Roche). The liver sample was placed in 600 µl of RIPA lysis buffer
and homogenized with an IKA T10 Basic S1 Dispersing Tool (IKA Works Inc,
Wilminsgton, NC). The homogenates were placed on ice for 5 mins before rotation at
4°C for 10 mins. The homogenates were subsequently centrifuged at 300 g for 15 mins at
4°C. The supernatant was transferred to fresh tubes and centrifuged at 14 000 RPM for
20 mins at 4°C. The supernatant was retained as the protein preparation. Equal
concentrations of total protein were normalized using a colorimetric BCA Protein Assay
(Pierce Corp., Madison, WI, USA). Each loading sample contained 30 µg of protein.
Samples were fractionated in gradient polyacrylamide gels (Invitrogen, Carlsbad, CA,
USA) and transferred onto polyvinylidenefidluoride membrane (Millipore, Etobicoke,
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Ontario, Canada). Blots were probed with FAS (catalog no. 3180S 1:1000, Cell
Signaling), ACCα (catalog no. 3662S 1:1000, Cell Signaling), LXRα (cat. no.sc-13068
1:5000, Santa Cruz Biotechnology), SREBP-1c (catalog no. sc-366, Santa Cruz
Biotechnology), p-ACCα (catalog no.3661P 1:1000, Cell Signaling) antibodies, and
monoclonal horseradish peroxidase-conjugated β-actin was used as the housekeeping
protein (catalog no. A3854 1:50000, Sigma-Aldrich). All antibodies were diluted in 5-7%
milk-1xTris-buffered

saline-Tween

20

(0.01%) buffer.

Horseradish

peroxidase

conjugated donkey anti-rabbit IgG (catalog no. 711035152 1:10000, Jackson
ImmunoResearch Laboratories, West Grove, PA) or horseradish peroxidase conjugated
donkey anti-mouse IgG (catalog no. 715001003 1:50000) diluted in 5-7% milk-1xTrisbuffered saline-Tween 20 (0.01%) were used as the secondary antibodies.
Immunoreactive bands were detected using an enhanced chemiluminescence detection
system (Thermo Scientific, Waltham, MA) and imaged with a VersaDoc Imaging System
(BioRad). Densitometry analysis was performed using Image Lab Software (BioRad).
2.2.3

Chromatin immunoprecipitation (ChIP)
Chromatin was extracted from liver tissues excised from PND180 male offspring

as previously described (153). In brief, a small piece of snap frozen liver was
homogenized in 0.5 mL of 1% formaldehyde and fixed for 10 mins at room temperature
to cross-link proteins and DNA. Glycine (0.125M, final concentration) was added to all
samples to terminate cross-linking. Samples were microfuged at 3000 RPM at room
temperature for 5 mins and supernatant was subsequently discarded. Samples were then
washed once with cold PBS and spun at 3000 RPM. Supernatant was discarded again and
500 µl of SDS lysis buffer (Millipore, Etobicoke, Ontario, Canada) with protease
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inhibitor cocktail (Roche, Mississauga, Ontario, Canada) was added to each sample.
Samples were incubated for 20 mins at 4°C and then sonicated to produce sheared,
soluble chromatin. The lysates were diluted ten times with ChIP dilution buffer
(Millipore, Etobicoke, Ontario, Canada) and aliquoted to volumes of 300 µl. Each of the
aliquots were precleared with protein A/G Plus agarose beads (20 µl, Millipore,
Etobicoke, Ontario, Canada) and rotated for 2 hours at 4°C. In order to pellet the beads,
samples were microfuged at 14000 RPM at 4°C, and the supernatant containing the
sheared chromatin was retained and placed in new tubes. The aliquots were incubated
with 3 µg of antibodies against LXRα (cat# sc-13068x, Santa Cruz Biotechnology, Santa
Cruz, California) or acetylated histone H3 (lysine 9,14, cat #05-399, Millipore,
Etobicoke, Ontario, Canada) and rotated overnight at 4°C. Two aliquots were reserved as
‘controls’ – one incubated without antibody (‘input’) and another with non-immune IgG
(Millipore, Etobicoke, Ontario, Canada). Protein A/G Plus agarose beads (60 µl) were
added to each tube and then rocked for 1 hour at 4°C. The immune complexes were
collected by centrifugation. The beads containing the immunoprecipitated complexes
were washed sequentially for 5 mins in wash buffer I (20 mM Tris-HCl, pH 8.1, 2 mM
EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), wash buffer II (same as I, except
containing 500 mM NaCl), wash buffer III (10 mM Tris-HCl, pH 8.1, 1 mM EDTA, 1%
NP-40, 1% deoxycholate, 0.25 M LiCl), and twice in Tris-EDTA (TE) buffer. The beads
were eluted with 250 µl elution buffer (1% SDS, 0.1mM NaHCO3 + 20 µg salmon sperm
DNA (Sigma-Aldrich, Oakville, Ontario, Canada) at room temperature. The elution step
was repeated once and eluates were combined. Samples were heated at 65°C for 4 hours
to reverse the crosslinking of the immunoprecipitated chromatin complexes and ‘input
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controls’ (10% of the total soluble chromatin). Proteinase K buffer was added to each
sample (50 mM Tris-Hydrochloride (HCl), pH 8.5, 1% SDS, 10 mM EDTA) and
incubated for 1 hour at 45°C. The DNA was purified by phenol-chloroform extraction
and DNA was precipitated overnight at -20°C in 100% EtOH containing 10% sodium
acetate (pH 5.6). The supernatant was removed and remaining pellets were dried. All
samples and ‘input’ controls’ were resuspended in 50 µl TE buffer prior to PCR analysis.
Real-time PCR was employed using forward (5’-GCCACGATGACCGGTAGTAA-3’)
and reverse (5’-GCGTTGCTAGGCAATAGGGT-3’) primers (PE Applied Biosystems,
Boston, MA, USA) that amplify a -690 to -561 bp region encompassing the published rat
FAS LXRE site (118). Using serial dilutions of rat liver chromosomal DNA, the primers
were demonstrated to have equal efficiency in priming to their target sequences (data not
shown).
2.3 Statistics
All results are expressed as the mean of arbitrary values ± the standard error of
the mean (SEM). All results from quantitative qRT-PCR, ChIP and western immunoblot
analysis were evaluated using an unpaired Student’s t test, where a p value of less than
0.05 was considered significant.
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CHAPTER 3 : RESULTS

3.1 Characterization of offspring exposed to maternal nicotine exposure during
pregnancy and lactation (MNE-PL)
3.1.1 Weight responses in male offspring exposed to MNE-PL
The birth weights of male MNE offspring were recorded throughout development.
At PND1, the weights of male MNE offspring were significantly lower compared to
control (p < 0.05) (Fig. 3.1.1A). At PND21, there was no significant difference in birth
weight between male offspring exposed to nicotine and control offspring (Fig. 3.1.1B).
By PND180, an increase in body weight from 563±5g to 605±4g (p<0.001) was observed
in nicotine-exposed male offspring (Fig. 3.1.1C). This increase in weight is noteworthy
considering that previous studies in this MNE-PL animal model have demonstrated that
the growth trajectory of nicotine-exposed offspring was significantly enhanced compared
to control, while nicotine administration had no effect on gestational length, maternal
food intake, maternal weight gain or litter size (196, 201).
3.1.2 Glucose, cholesterol and triglyceride measurements in control and nicotine
exposed male offspring
MNE-PL led to a significant increase in fasting serum triglycerides in male but
not female offspring at PND180 (Fig. 3.1.2C). Similarly, hepatic triglyceride levels were
significantly elevated in male offspring compared to control, although female offspring
were not examined (Fig. 3.1.2D). Analysis of circulating levels of fasting glucose and
cholesterol were not significantly altered between control and MNE-PL male offspring at
PND180 (Fig 3.1.2A-B).

36

Fig. 3.1.1 The effect of maternal nicotine exposure during pregnancy and lactation on
body weight in male PND1 (A), PND21 (B) and PND180 (C) rat offspring. Results are
expressed as the mean ± SEM. Nicotine effects were determined using a Student’s t test.
* = (p < 0.05); n = 6/group.
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Fig. 3.1.2 The effect of MNE-PL on circulating levels of glucose (A), cholesterol (B),
triglycerides (C) and hepatic triglycerides (D) in PND180 male rat offspring. Results
are expressed as the mean ± SEM. Nicotine effects were determined using a Student’s t
test. For data in Figure 3.1.2C, the t test was performed with the data within each gender.
* = (p < 0.05); n = 7-17/group.
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3.2 Long-term effects of MNE-PL on hepatic lipogenic genes in offspring
3.2.1 MNE-PL increased the steady-state mRNA levels of fatty acid synthesis enzymes in
the liver of male PND180 offspring
In order to elucidate the molecular mechanisms underlying the elevated
triglyceride levels in nicotine-exposed male adult rat offspring, we next examined the
hepatic enzymes involved in the fatty acid synthesis pathway leading to de novo
triglyceride production (85, 87, 88). qRT-PCR revealed significant increases (p<0.05) in
hepatic fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACCα) mRNA, both
enzymes involved in the initial steps of fatty acid synthesis, in male (Fig. 3.2.1.1A-B) and
female (Fig. 3.2.1.2A-B) PND180 MNE-PL offspring (85, 87). Interestingly, no
significant changes in the hepatic steady-state mRNA levels of stearoyl-CoA
dehydrogenase 1 (SCD-1) were observed in male (Fig. 3.2.1.1C) or female offspring
(Fig. 3.2.1.2C).
However, due to the lack of significant change in circulating triglyceride levels,
PND180 female offspring were not further investigated in this study. More importantly,
this model has been previously demonstrated to exhibit early life programming effects in
a sexually dimorphic manner, which was not the focus of this investigation (195).
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Fig. 3.2.1.1 The effect of MNE-PL on hepatic steady-state mRNA levels of FAS (A),
ACCα
α (B), and SCD-1 (C) in PND180 male rat offspring. RNA was extracted and
mRNA levels were assessed using qRT-PCR with primers specific for FAS, ACCα and
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 5-10/group.
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Fig. 3.2.1.2 The effect of MNE-PL on hepatic steady-state mRNA levels of FAS (A),
ACCα
α (B), and SCD-1 (C) in PND180 female rat offspring. RNA was extracted and
mRNA levels were assessed using qRT-PCR using primers specific for FAS, ACCα and
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined using
a Student’s t test. * = p < 0.05); n = 4-5/group.
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3.2.2 MNE-PL correspondingly increased the protein levels of hepatic enzymes involved
in fatty acid synthesis in male PND180 offspring
As differences were found in the steady-state mRNA levels of hepatic lipogenic
genes (e.g. FAS and ACCα), we next performed western immunoblot analysis to
determine changes at the protein level. At PND180, MNE-PL led to a significant increase
in FAS protein levels (Fig. 3.2.2.1). Despite changes in mRNA levels, there were no
corresponding changes in protein levels of ACCα (Fig 3.2.2.2A). Subsequently, the
inactivated form of ACCα was explored to determine if levels of inactivated ACCα were
altered due to MNE-PL (203). Western immunblotting revealed no difference in
phosphorylated-ACCα (Fig. 3.2.2.2B) protein levels between PND180 nicotine exposed
and control offspring.
3.2.3 MNE-PL leads to long-term increases in hepatic protein levels of LXRα
To begin to decipher the underlying mechanisms behind the increase in FAS
expression in PND180 male MNE-PL offspring, we next investigated hepatic levels of
LXRα and SREBP-1c, both regulators of FAS (118, 204). At PND180, MNE-PL led to a
significant increase in hepatic LXRα protein levels (Fig. 3.2.3A) in male offspring
compared to control, while no difference was observed in SREBP-1c protein expression
(Fig. 3.2.3B).
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Fig. 3.2.2.1 MNE-PL leads to an increase in FAS protein levels in PND180 male
offspring. Protein was extracted and the expression of FAS was measured using western
immunoblot analysis. The protein levels were quantified using densitometry and
normalized to the protein levels of a housekeeping protein, β-actin. Results are expressed
as the mean ± SEM. Nicotine effects were determined using a Student’s t test. * = p <
0.05); n = 6-7/group.
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Fig. 3.2.2.2 Exposure to nicotine during pregnancy and lactation does not
influence ACCα
α (A) and p-ACCα
α (B) protein levels in PND180 male offspring.
Protein was extracted and the expression of ACCα and p-ACCα was measured
using western immunoblot analysis. The protein levels were quantified using
densitometry and normalized to the protein levels of a housekeeping protein, βactin. Results are expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 5-7/group.
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Fig. 3.2.3 MNE-PL leads to an increase in hepatic LXRα
α protein levels in
PND180 male rat offspring. Protein was extracted and the expression of LXRα
(A) and SREBP-1c (B) was analyzed using western immunoblot analysis. The
protein levels were quantified using densitometry and normalized to a
housekeeping protein, β-actin. Results are expressed as the mean ± SEM. * = p <
0.05; n= 5-7/group.
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3.2.4 MNE-PL leads to increased LXRα binding to the putative LXRE on the FAS
promoter in PND180 male rat offspring
The increase in LXRα protein expression suggests that LXRα may be facilitating
the increase in FAS protein and mRNA expression in adult male offspring exposed to
nicotine during pregnancy and lactation. To explore this further, we employed chromatin
immunoprecipitation (ChIP) to examine the in vivo binding of LXRα to its putative LXR
binding element (LXRE) on the proximal rat promoter (-669 to -665 bp) of FAS (118).
Real-time primers were designed to surround the LXRE of the FAS gene and were
demonstrated to equally amplify their target sequences over a range of chromatin
concentrations (data not shown). While not significant (p=0.13), male PND180 MNE-PL
offspring in this small samples size (n=5) were observed to have increased LXRα binding
at the putative LXRE of the FAS promoter (Fig. 3.2.4). Nonimmune IgG displayed
negligible binding compared to LXRα binding to the FAS promoter.
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Fig. 3.2.4 MNE-PL increases LXRα
α binding to the LXRE of the FAS promoter
in the liver of PND180 male offspring. The in vivo binding of LXRα to the hepatic
LXRE of the FAS promoter in male rat offspring at PND180 was assessed by
chromatin

immunoprecipitation.

Briefly,

cross-linked

chromatin

was

immunoprecipitated using an antibody specific for LXRα and the relative abundance
of a region surrounding the LXRE (-669 to -655 bp) of the FAS promoter was
quantified using qRT-PCR. The relative level of immunoprecipitated DNA was
normalized to total genomic DNA for each sample. The effect of nicotine was
determined using a Student’s t test. Results are expressed as the mean ± SEM. * = p
< 0.05; n= 5/group.
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3.3 Epigenetic alterations of the hepatic fatty acid synthesis pathway in adult rat
offspring due to MNE-PL
3.3.1 MNE-PL induced transcriptional activation of hepatic FAS expression is associated
with an increase in the acetylation of histone H3 [K9,14] surrounding the LXRE of
the FAS promoter region in PND180 male offspring
Since LXRα has been demonstrated to enhance the acetylation of histone H3
[K9,14] to increase hepatic FAS transcription (152), we next employed ChIP to
investigate if chromatin remodeling could be a factor influencing the observed increase in
FAS mRNA and protein levels in MNE-PL offspring. The acetylation of histone H3 [K9,
14] is well known to be associated with chromatin activation (136). ChIP revealed that
male MNE-PL offspring in this small samples size (n=5) were trending towards an
significant increase (p=0.09) in the acetylation of histone H3 [K9,14] surrounding the
putative LXRE (-669 to -655 bp) of the FAS promoter (Fig. 3.3.1) (118). Nonimmune
IgG displayed negligible binding compared acetylation of histone H3 [K9,14]
surrounding the FAS promoter.
3.3.2 The effects of MNE-PL on the steady-state mRNA levels of histone modifying
enzymes (Sirt-1 and p300) in the livers of PND180 male offspring
As differences were found in the levels of acetylation of histone H3 [K9, 14]
surrounding the putative LXRE of the FAS promoter, we investigated possible
mechanisms responsible for the alterations in the epigenetic status of adult male
offspring. qRT-PCR revealed no difference in mRNA expression of Sirt-1 (Fig. 3.3.2A)
or p300 (Fig. 3.3.2B), known histone deacetylases and acetyltransferases, respectively
(141, 145).
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Fig. 3.3.1 MNE-PL increases the acetylation of histone H3 [K9,14]
surrounding the LXRE of the FAS promoter in the liver of PND180 male
offspring. Briefly, cross-linked chromatin immunoprecipicated using an antibody
specific for acetylated histone H3 [K9,14] was isolated and the relative abundance
of a region surrounding the LXRE (-669 to -655 bp) of the FAS promoter was
quantified using qRT-PCR. The relative level of immunoprecipitated DNA was
normalized to total genomic DNA for each sample. Results are expressed as the
mean ± SEM. Nicotine effects were determined using a Student’s t test. * = p <
0.05; n= 5/group.

49

Fig. 3.3.2 MNE-PL does not influence hepatic steady-state mRNA levels of
Sirt-1 (A) and p300 (B) in PND180 male rat offspring. RNA was extracted and
mRNA levels were assessed using qRT-PCR with primers specific for Sirt-1 and
p300. Results are expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 5/group.
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3.4 Direct effects of MNE-PL on hepatic fatty acid synthesis in offspring
3.4.1 The effects of MNE-PL on hepatic fatty acid synthesis in PND1 and PND21 male
offspring
Earlier developmental time points in offspring were examined in order to
determine whether MNE-PL directly leads to the elevations in triglyceride levels
observed in male offspring at PND180. qRT-PCR analysis found no differences in FAS,
ACCα and SCD-1 mRNA levels between PND1 control and MNE offspring (Fig.
3.4.1.1A-C).
Similarly, analysis of FAS, ACCα and SCD-1 mRNA levels via qRT-PCR
revealed no difference in PND21 male control and nicotine exposed offspring (Fig.
3.4.1.2A-C). Importantly, the PND21 time point represents the longest period of exposure
(21 days) to nicotine in offspring.
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Fig. 3.4.1.1 MNE-PL does not influence hepatic steady-state mRNA levels of ACCα
α
(A), FAS (B), and SCD-1 (C) in PND1 male rat offspring. RNA was extracted and
mRNA levels were assessed using qRT-PCR using primers specific for FAS, ACCα and
SCD-1. Results were expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 2-5/group.
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Fig. 3.4.1.2 MNE-PL does not influence hepatic steady-state mRNA levels of ACCα
α
(A), FAS (B), and SCD-1 (C) in PND21 male rat offspring. RNA was extracted and
mRNA levels were assessed using q-RT-PR using primers specific for FAS, ACCα and
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 4-5/group.
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CHAPTER 4 : DISCUSSION

4.1 Clinical relevance of the study
In this study I present evidence that MNE-PL leads to hypertriglyceridemia in
PND180 male rat offspring. My data suggests that this effect is due to increased de novo
hepatic triglyceride synthesis. Specifically, I demonstrated that FAS expression was
enhanced due to increased LXRα protein levels and binding to the LXRE of the FAS
promoter in PND180 male MNE-PL offspring. This increase in LXRα binding at the FAS
promoter was associated with enriched histone H3 acetylation [K9,14] at the LXRE site,
previously shown to lead to FAS transcriptional activation (152). Given the wellestablished link between an adverse in utero environment and the development of
metabolic dysfunction long-term (158, 205), this study sheds light on possible molecular
mechanisms that mediate the programming of obesity in children exposed to smoke in
utero (8). My study also raises questions regarding the safety of NRT during pregnancy
and long-term consequences for offspring.
4.2 Examining the mechanisms of nicotine action on hepatic fatty acid synthesis
In this thesis, I investigated the influence of MNE-PL on the hepatic fatty acid
synthesis pathway. I present evidence that MNE-PL leads to elevated levels of hepatic
and circulating triglyceride levels, concomitant with alterations to fatty acid biosynthetic
enzyme expression in PND180 male offspring. MNE-PL did not affect circulating
glucose or cholesterol levels in offspring. My findings support human studies that
demonstrated adult women exposed to tobacco in utero exhibit elevated triglyceride
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levels in adulthood (13). Livers of PND1 and PND21 MNE-PL offspring were examined
to determine whether nicotine directly augments triglyceride levels. These earlier
developmental time points represent different windows of direct nicotine exposure in
fetal and neonatal life. PND1 and PND21 MNE-PL offspring did not exhibit any
significant differences in the expression of FAS, ACCα, or SCD-1 compared to control
offspring. Consequently my results suggest that elevated triglycerides were not a direct
result of nicotine exposure, as we would have expected to observe alterations in target
gene expression at weaning, following the longest window of direct nicotine exposure.
Moreover, only a subset of primary human hepatic stellate cells express the neuronal
subunits of nAcHR (α3,α6, α7, β2 and β4) (206). Together, given the lack of nAcHR
subunit expression in hepatocytes and unaltered fatty acid synthesis in early life, it is
highly conceivable that nicotine induced alterations in long-term fatty acid synthesis and
triglyceride levels are a result of indirect mechanisms.
4.3 Possible mechanisms underlying the effect of MNE-PL on long-term
programming of hypertriglyceridemia in offspring
In this study, MNE-PL resulted in significantly heavier male offspring compared
to control offspring at PND180. These results support findings from human studies that
have repeatedly demonstrated an increase in the risk of obesity in children (ages 2 – 33
years old) exposed to smoking during pregnancy regardless of parental socioeconomic
background, infant feeding patterns and gestational weight gain (8, 11, 207-210). My rat
model suggests that nicotine alone leads to the development of obesity and elevated
triglycerides in children exposed to smoking in utero (209). Despite being heavier in later
life, I found that MNE-PL offspring at PND1 weigh less compared to control offspring.
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Children of smoking mothers also shared this surprising characteristic, as exposed
children are at higher risk for being low birth weight compared to unexposed offspring
(208, 211, 212). Further studies demonstrate that fetal growth restriction is more likely
responsible for low birth weight in children rather than preterm delivery (208, 211-213).
Other animal models of MNE have also proposed that nicotine alone can impair growth
in offspring. It was found that nicotine injections of 2mg/kg/day during gestation in rats
led to lower average fetal weight in utero compared to control fetuses (214). Similarly,
rat offspring exposed to 6mg/kg/day of nicotine during early postnatal life gained
significantly less weight per day compared to control offspring (215). However, these
nicotine-exposed pups caught up in size by PND18. While these studies suggest that
nicotine alone can impair fetal growth, it is important to note that these animal models
utilized higher concentrations of nicotine compared to the model of MNE-PL used in my
study. Therefore, future studies should closely monitor the growth of MNE-PL offspring
to ascertain whether a moderate dosage of nicotine for a longer period of time lead to
comparable growth impairments in offspring.
To resolve the two extreme phenotypes that are observed in response to nicotine
exposure in perinatal life, my data suggests that MNE-PL offspring undergo catch up
growth. A study has demonstrated that babies of smoking mothers tended to be lighter at
birth but caught up in weight to children of non-smoking mothers by 12 months of age
(216). Specifically, male children caught up at a faster rate compared to female children
(216). Furthermore, children that were born small and were able catch up in bodyweight
had higher percentages of body fat and increased BMI in early life compared to other
children (176). Therefore, catch up growth may program offspring to overshoot normal

57

growth trajectories leading to a higher likelihood of developing characteristics that are
predictive of adult obesity (176). Although the mechanisms by which children are able to
catch up in growth are largely unknown, it has been postulated that low leptin levels in
low birth weight babies may signal for greater food intake (176). The connection between
catch up growth and differences in nutritional intake has been investigated by comparing
breast-fed and formula fed preterm babies. Formula fed babies were found to experience
high neonatal growth during the first 2 weeks following birth and this was associated
with higher markers of insulin resistance and an atherogenic lipoprotein profile that was
observed up to 16 years later (217, 218). Since catch up growth in babies was found
irrespective of birth weight, researched proposed that the programming of metabolic
outcomes largely occurs antenatally. Therefore in this study, MNE-PL may impair fetal
development leading to subsequent catch growth and the programming of
hypertriglyceridemia in offspring.
4.4 Catch up growth and ER stress
Interestingly, our laboratory has demonstrated that rat offspring exposed to an
adverse in utero environment followed by rapid catch up growth in postnatal life, exhibit
increased ER stress (219). Various insults such as glucose deprivation, changes in
oxidation-reduction balance, infection and development of secretory cells can all lead to
the misfolding of proteins and initiate the unfolded protein response (UPR) (220, 221).
The UPR response helps cells cope with an overloaded ER by decreasing translation,
increasing efflux and stimulating the degradation of proteins (220). The UPR leads to the
phosphorylation of the eukaryotic initiation factor 2α (eIF2α), which leads to the
attenuation of further translation (220). It also increases chaperone protein levels (e.g.
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glucose regulated proteins Grp78 and Grp94) to facilitate increased folding and induces
the splicing of the X-box binding protein (Xbp-1) to increase protein degradation (220).
ER-stress induced apoptosis is activated if a cell is overwhelmed by the amount of
misfolded protein (221). Specifically, our laboratory has demonstrated that postnatal
catch up growth is associated with elevated levels of ER chaperone protein Grp78 and
enhanced phosphorylation of eIF2α long-term (219). Since our MNE-PL model appears
to lead to catch up growth in offspring, future studies should investigate whether hepatic
ER stress pathways are activated in conjunction with alterations in fatty acid and
triglyceride synthesis.
The role of ER stress in models of catch up growth is an attractive mechanism to
explain in part, the underlying mechanisms of fetal programming. Indeed, studies have
already postulated that obesity induces hepatic insulin resistance through elevated ER
stress signaling in the liver of rodent models (222, 223). Notably, my preliminary data in
PND180 male offspring exposed to MNE-PL, exhibited increased Grp78 protein levels
(Fig. 4.4).
Yet, the involvement of ER stress in the long-term programming of
hypertriglyceridemia in nicotine-exposed offspring has not been fully elucidated.
Although nicotine did not have a direct effect in my MNE-PL model, it would be
interesting to assess if nicotine could directly induce ER stress in PND1 or PND21
offspring, or if ER stress is activated due to catch up growth. It is noteworthy that one
study has demonstrated that antagonism of LXRα protects against steatosis by decreasing
ER stress (224). This study presents a novel mechanism by which ER stress mediates the
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development of liver pathology through LXRα activation. Given the increase in LXRα in
MNE-PL offspring and the association between ER stress and catch up growth, future
studies will evaluate ER stress markers in the liver of PND180 male offspring. It is
plausible that nicotine induced ER stress may be causing permanent changes in hepatic
function via the aberrant activation of LXRα in MNE-PL offspring.

Fig. 4.4 MNE-PL leads to increased Grp78 protein expression in PND180 male
offspring. Protein was extracted and the expression of Grp78 was measured using
western immunoblot analysis. The protein levels were quantified using
densitometry and normalized to the protein levels of a housekeeping protein, βactin. Results are expressed as the mean ± SEM. Nicotine effects were determined
using a Student’s t test. * = p < 0.05); n = 8/group.
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4.5 Molecular mechanisms underlying elevated triglycerides in adult MNE-PL
offspring
The three main sources of free fatty acids used for triglyceride synthesis in the
liver include de novo, circulating, and dietary (87). Human and animal studies have both
demonstrated that alterations in fatty acid synthesis lead to impairments in triglyceride
homeostasis (87, 115, 118, 225). In the present study, I have demonstrated elevations in
the steady-state mRNA levels of FAS and ACCα in the liver of male MNE-PL offspring
at PND180. MNE-PL offspring also exhibited a corresponding increase in FAS protein
expression suggesting that alterations in FAS play a central role in de novo triglyceride
synthesis. Studies in rodent models of obesity associated with elevated plasma
triglyceride levels, have similarly demonstrated an increase in hepatic FAS protein
expression (226, 227). Moreover, de novo fatty acid synthesis is considered a dynamic
process as human studies have shown that the rate synthesis can be drastically altered in
various disease states (228, 229). Taken together, these data suggest that nicotine
exposure may permanently increase triglyceride levels, in part, via a FAS-dependent
pathway.
To date, I have only examined de novo triglyceride synthesis as the main source
for elevated triglycerides observed in PND180 MNE-PL offspring. However, other
mechanisms could be contributing to the development of hypertriglyceridemia in nicotine
exposed offspring including differences in food consumption and adipose tissue
distribution. Since high carbohydrate diets have been shown to increase de novo fatty
acid synthesis and plasma triglyceride levels in both rodents and humans, future studies
should closely monitor post-weaning food consumption in nicotine-exposed offspring
(230-232). In addition, obtaining adipose tissue from MNE-PL offspring will also be
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pursued in later studies, considering elevated amounts of body fat is a predictor of
triglyceride levels in humans (233).
Given the increase in expression of fatty acid biosynthetic genes, I next
investigated changes in regulatory mechanisms. The expression of FAS is under the
direct control of various transcription factors including LXRα (-669 to -655 bp), SREBP1c (-71 to -54 bp), and ChREBP (-7214 to -7190 bp) (117, 119, 234). My study
determined that there were significantly higher levels of LXRα protein in MNE-PL
offspring compared to control offspring. In parallel, unpublished data from our laboratory
has demonstrated that following short-term neonatal exposure to an LXR agonist leads to
higher triglycerides levels in rat offspring (Fig. 4.5). Models involving treatment with
LXRα agonists have demonstrated similar elevations in plasma triglycerides along with
an induction of hepatic FAS expression (118). Likewise, LXR deficient mice treated with
LXRα agonist do not exhibit an increase in triglyceride levels (204). Therefore, LXRα
activation is imperative to FAS activation and triglyceride synthesis.
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Fig. 4.5 Treatment with LXR agonist, GW3965, during pregnancy in rats led
to increased circulating triglyceride levels in offspring. Results are expressed as
the mean ± SEM. LXR agonist effects were determined using a Student’s t test. * =
(p < 0.05); n = 6-9/group.
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To determine whether the increase in LXRα and its target, FAS, were
functionally related, ChIP experiments were carried out to measure in vivo binding of
hepatic LXRα to the promoter of FAS in PND180 male offspring. ChIP studies revealed
increased LXRα binding surrounding the putative LXRE (-669 to -655 bp) of the FAS
promoter (117). My results suggest that an elevation in hepatic LXRα expression
mediates the transcriptional activation of FAS. Remarkably, other models of fetal
programming have demonstrated that LXR and LXR-target genes are susceptible to
permanent programming changes (153, 155, 235). Thus, it is conceivable that nicotinemediated changes in triglyceride levels are occurring in part through prolonged or even
permanent increase in FAS activation. It would be interesting to further ascertain the role
of LXRα in modulating permanent elevations in FAS expression by undertaking in vitro
studies. In vitro studies involving the treatment of hepatocytes with LXRα antagonists
such as piperine, followed by the analysis of FAS expression and ChIP analysis would
help confirm whether permanent FAS activation in MNE-PL offspring is attributed
directly to LXRα (224).

While it has been established that LXRα plays a large role in the regulation of
FAS, other regulatory pathways should be considered in future studies. SREBP-1c is a
transcription factor that is activated in its cleaved form and inhibited in the presence of
sterols (119, 236, 237). Similar to LXRα, SREBP-1c can directly activate certain fatty
acid biosynthetic enzymes including FAS, ACCα and SCD-1 (119, 238, 239). In my
study I found no difference in SREBP-1c protein expression between PND180 MNE-PL
and control offspring. My findings support previous studies demonstrating augmented
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triglyceride levels in obese mice despite diminished SREBP-1c expression (240). For this
reason, SREBP-1c is considered an auxiliary regulator of fatty acid synthesis that is under
the direct control of LXRα (115, 236). Future studies could investigate the carbohydrateresponsive element binding protein (ChREBP). ChREBP is a transcription factor from the
same family as SREBP-1c that heterodimerizes with the protein Max-like protein X
(Mlx) (241). It binds to carbohydrate response elements (ChoRE) of glucose responsive
targets found throughout the de novo lipogenic pathway (241, 242). ChREBP is
ubiquitously expressed, with the highest expression found in the liver, brown and white
adipose tissues, small intestine, kidneys and muscle (242). ChREBP knock-out mice
exhibited lower levels of hepatic FAS and ACCα and a 65% decrease in fatty acid
synthesis rates compared to control mice. Importantly, there were no changes in SREBP
levels, meaning that the loss of ChREBP was not mediated via SREBP-1c (242).
Consequently, ChREBP is another independent regulatory mechanism that should be
considered for future investigation in adult MNE-PL male offspring.
4.6 The role of epigenetics in the fetal programming of hypertriglyceridemia in adult
MNE-PL offspring
In this present study, I have demonstrated an increase in acetylation of histone H3
surrounding the LXRE of the hepatic FAS gene in PND180 MNE-PL offspring. My
findings suggest that maternal nicotine exposure leads to long-term posttranslational
histone modifcations that facilitate increased transcription of FAS. While my results
demonstrate changes in chromatin remodeling due to MNE-PL, the effect of nicotine on
epigenetic changes is virtually unknown. In vitro studies in primary neuronal cortical
cells and primary human lymphocytes have shown that nicotine exposure leads to a more
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transcriptionally ‘permissive’ chromatin environment through alterations in the
expression of HMTs such as GLP, G9a and Setdb1 (243). Similar histone modifications
were observed in vivo. A single intraperitoneal injection of 3mg/kg of nicotine was able
to elicit measurable changes in mouse cortical extracts 6 hours following injection (243).
It would be interesting to determine whether measurable changes occur in methylation
and HMT expression in my model of short-term neonatal exposure to nicotine. Future
studies should investigate all developmental time points (PND1, 21 and 180) in MNE-PL
offspring, to examine whether MNE results in posttranslational histone modifications that
precede the development of long-term hypertriglycerdemia in offspring.
Lastly, mRNA levels of Sirt-1 and p300, known histone acetyltransferases and
histone deacetylases, respectively, were measured in order to understand the mechanisms
underlying nicotine-induced epigenetic modifications (141, 145). While MNE-PL does
not influence Sirt-1 or p300 mRNA expression in PND180 male offspring, I was only
able to measure the indirect action of these enzymes. In future studies, I would like to
employ a similar ChIP study to investigate changes in the in vivo binding of Sirt1 or p300
to the FAS promoter directly.
4.7 Early folic acid intervention in the prevention of permanent nicotine-induced
disease outcomes in rat offspring
Since the development of the liver continues during early postnatal life, it is
plausible that intervention during perinatal life could help reverse or prevent nicotineinduced hypertriglyceridemia in adulthood (244). For example, short-term injections of
Exendin-4 in neonatal life have been found to prevent oxidative stress, impaired
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hepatic glucose production and hepatic insulin resistance normally exhibited in
intrauterine growth restricted (IUGR) rat offspring (245).
Interestingly, folic acid supplementation has been demonstrated to reduce longterm hypertriglycidemia in IUGR piglets via increased methylation of the promoter of
LXR-target genes (246). Folate, and its synthetic form, folic acid, act as essential
cofactors for biochemical reactions, namely the formation of S-adenosylmethionine, the
main methyl donor for methylation (247).

A clinical study has demonstrated that

differences in DNA methylation patterns can be detected in children exposed to smoke in
utero (248). Futhermore, folic acid has been shown to alleviate ER stress (249, 250).
Taken together, it is conceivable that additional supplementation of folic acid may
prevent adult onset hypertriglyceridemia in offspring exposed to nicotine through the
prevention of aberrant epigenetic modulation and/or reduction of ER stress.
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Fig. 4.7 Schematic overview of animal model of MNE-PL and folic acid
intervention
Future animal studies will investigate whether dietary folate supplementation can prevent
or reduce nicotine-induced hypertriglyceridemia. I will administer nicotine alone, and in
combination with folic acid to pregnant rats at clinically relevant doses to female rats
during pregnancy and lactation (Fig. 4.7). I will evaluate whether folic acid
supplementation prevents hypertriglyceridemia and/or activation of LXRα target genes in
adult rat offspring. I will also assess whether folic acid supplementation reduces ER
stress in liver of PND180 offspring.
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